What Are Some Examples Where MRI Played a Biomarker Role in OA Clinical Pharmaceutical Trials?
• In patients with knee pain on efficacious doses of NSAIDs or acetaminophen, a decrease in effusion volume (quantified by gadolinium-enhanced T1 imaging) was observed and rapidly reversed when treatment was withdrawn. • In a placebo-controlled, double-blind study of 377 knee OA patients, changes in MRI assessment of subchondral bone marrow abnormalities were observed within three months of treatment and were positively correlated with type II collagen degradation (determined by urinary CTX-II). MRI imaging is a sensitive and early marker of OA that can correlate with drug efficacy. (Contributed by Rick Walovitch, Ph.D., WorldCare Clinical) CONCLUSION The complexity of knee osteoarthritis etiologies complicates the search for a single disease modifying therapeutic approach. Current treatment emphasizes conservative management including mechanical joint preservation measures. MRI depicts the whole joint nature of the disease and serves as a barometer of its time course. Research and rep
Related Questions
- How much does related clinical practice experience count for admission and what are some examples of these experiences?
- Why do pharmaceutical companies increasingly shift their clinical drug trials to developing countries?
- What Are Some Examples Where MRI Played a Biomarker Role in OA Clinical Pharmaceutical Trials?
